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E-mail address: adiehl@informatics.jax.org (A.D. DThe Cell Ontology (CL) aims for the representation of in vivo and in vitro cell types from all of biology. The
CL is a candidate reference ontology of the OBO Foundry and requires extensive revision to bring it up to
current standards for biomedical ontologies, both in its structure and its coverage of various subﬁelds of
biology. We have now addressed the speciﬁc content of one area of the CL, the section of the ontology
dealing with hematopoietic cells. This section has been extensively revised to improve its content and
eliminate multiple inheritance in the asserted hierarchy, and the groundwork has been laid for structur-
ing the hematopoietic cell type terms as cross-products incorporating logical deﬁnitions built from rela-
tionships to external ontologies, such as the Protein Ontology and the Gene Ontology. The methods and
improvements to the CL in this area represent a paradigm for improvement of the entire ontology over
time.
 2010 Elsevier Inc. All rights reserved.1. Introduction
The Cell Ontology (CL) is a biomedical ontology originally built
to represent in vivo and in vitro cell types, including those observed
in speciﬁc developmental stages, of all the major model organisms
[1]. The CL now aims to become a reference ontology within the
Open Biomedical Ontology (OBO) Foundry (www.obofoundry.org)
[2]. The CL both serves the terminology needs of data annotation
and provides a base ontology fromwhich compound terms in other
ontologies can be derived by means of cross-product term forma-
tion [3]. Within the Mouse Genome Informatics resource
(www.informatics.jax.org), for instance, the CL is used in conjunc-
tion with Gene Ontology (GO) during annotation of mouse gene
products to indicate the cell type in which a gene product is active,ll rights reserved.
e Informatics, The Jackson
SA. Fax: +1 207 288 6131.
iehl).an approach that is now being adopted by other model organism
databases within the GO Consortium. In ontology development
for the GO, CL terms are employed in the formation of new GO
terms using the cross-product of core GO biological process terms
and CL terms: for instance, the GO term ‘‘leukocyte differentiation”
can be deﬁned using the GO term ‘‘cell differentiation” and the CL
term ‘‘leukocyte” [4 (this issue)]. The Immunology Database and
Analysis Portal (www.immport.org) is using the CL as a reference
of cell types for the mapping of results from the analysis of ﬂow
cytometry data. The CL is also frequently used to compose descrip-
tions of phenotypes [5].
The Cell Ontology is currently constructed using two relations,
is_a and develops_from. The ﬁrst relation is used to relate speciﬁc
cell types to more general cell types (for example, between ‘‘T cell”
and ‘‘lymphocyte”); the latter relation is used to indicate cell line-
age relationships (for example, between ‘‘neuron” and ‘‘neuro-
blast”). The ontology, as it was initially developed, relies upon a
number of artiﬁcial high-level terms to capture types of cellular
qualities, such as ‘‘cell in vivo,” ‘‘cell by organism,” and ‘‘cell by
76 A.D. Diehl et al. / Journal of Biomedical Informatics 44 (2011) 75–79class,” a term which itself has the is_a child terms ‘‘cell by func-
tion,” ‘‘cell by histology,” ‘‘cell by lineage,” ‘‘cell by ploidy,” etc.
These subclasses of cells have further is_a children denoting more
speciﬁc qualities of cells. Depending on the qualities of a particular
cell type it may have one or more of these terms as is_a ancestors.
For instance, in the original form of the ontology the cell type
‘‘macrophage” is a direct subtype of ‘‘mononuclear phagocyte”
and ‘‘professional antigen presenting cell,” and an indirect subtype
of ‘‘cell by function,” ‘‘cell by histology,” ‘‘cell by nuclear number,”
and ‘‘animal cell” (Fig. 1A).
With its multiple inheritance structure, the original CL can be
described as having separate ontologies of cell types delineated
by particular cellular qualities overlaid upon each other, i.e. an
ontology with multiple axes of differentia that are variously andFig. 1. Term placement for cell type term ‘‘macrophage” in the Cell Ontology. (A) In the
incorporating the revisions to the hematopoietic cell types.sometimes arbitrarily applied to individual cell types. Furthermore
the high-level terms themselves do not represent actual cell types,
so the ontology is not a true is_a hierarchy. This unwieldy ontolog-
ical construct is not ideal for developing proper inference about
cell types, nor does it always provide obvious placement of new
cell type terms.
Discussions among interested parties in the past few years have
focused on how best to restructure the CL to eliminate the com-
plexity of its multiple inheritance structure. One way to achieve
this restructuring is to use an increasingly common methodology
for developing ontologies: Assign logical deﬁnitions to classes
based on their properties, and then let automated tools – called
reasoners – infer the multiple inheritance hierarchy. This strategy
exploits the work done in other ontologies. For example, neuronsoriginal Cell Ontology, showing its multiple inheritance structure. (B) In the ‘‘CL1.5”
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released, and the ontology of chemical entities can be used to
determine the subsumption relationships between types of
neuron.
The hematopoietic/immune cell types are of particular interest
because of their roles in the immune response and consequent
involvement in human health and disease. These cell types in par-
ticular have been the focus of two rounds of intensive curation in
recent years. A set of improvements for hematopoietic cells was
done in 2006 in conjunction with the revision of the terms for
immunological processes in the GO [6], (Diehl, unpublished). At
that time 80 new hematopoietic cell type terms were introduced,
many other terms were revised, and many improvements in ontol-
ogy structure were made for these speciﬁc cell types.
A second, more extensive round of revisions to the hematopoi-
etic cell type terms in CL is described herein. These revisions grew
out of the proceedings of a National Institute of Allergy and Infec-
tious Disease (NIAID) sponsored ‘‘Workshop on Immune Cell Rep-
resentation in the Cell Ontology,” held in May 2008, where domain
experts and biomedical ontologists worked together on two goals:
(1) revising the existing terms and developing additional terms for
T cells, B cells, natural killer cells, monocytes and macrophages,
and dendritic cells, and (2) establishing a new paradigm for a com-
prehensive revision of the whole of the CL. These changes in the
representation of hematopoietic cells were needed to represent
these cell types in a more complete and accurate manner. The goals
were to represent all major hematopoietic cell types identiﬁed in
the literature in the ontology and to deﬁne these cell type in an
in-depth manner that greatly increases the descriptiveness of the
ontology for data annotation and logical inference.2. Methods
The NIAID workshop attendees discussed how best to charac-
terize hematopoietic/immune cell subsets, as well as how to im-
prove the overall ontological structure of the corresponding
portions of the CL and of the CL ontology in general. The consensus
view was that the current multiple inheritance structure of the CL
is unsustainable and that existing and new terms for hematopoi-
etic cells should be logically deﬁned via their structural parts and
qualities as represented in other ontologies. Much discussion cen-
tered on what might be the optimal axis of differentia for these
hematopoietic terms. It was recognized that, in many cases, these
cell types are deﬁned largely, but not solely, by the expression of
particular marker proteins either at the cell surface (e.g. receptor
proteins) or internally (e.g. transcription factors). The presence of
these proteins as part of a cell is considered a structural feature
of the cell, and we have chosen to use the relation has_part (or
an appropriate sub-relation) from the OBO Relation Ontology
(RO) to relate particular cell types to protein terms from the Pro-
tein Ontology (PRO) or protein complex terms from the cellular
component ontology of the Gene Ontology (GO) [7,8].
However, for certain cell types such as macrophages, the full
molecular characterization of different types is still not complete
in the literature, and anatomical location effectively serves as a
major differentia for these cells, which can be expressed via the
relation part_of. For other cell types, functional or lineage criteria
serve as differentia for the complete deﬁnition of the cells. Func-
tional criteria include the ability to execute or participate in partic-
ular processes that relate to individual cell types, such as those
referred to by the GO biological process terms ‘‘leukocyte mediated
cytotoxicity” or ‘‘cytokine production,” or processes that involve
coordination of multiple cell types, such as that referred to by
the GO term ‘‘T-helper 1 type immune response.” For this type of
criteria we will use the capable_of type-level relation, deﬁned interms of the bearer_of and the realized_by type-level relations
(these two relations will be incorporated in a future version of
the RO). Formally, C capable_of P if there exists some D such that
C bearer_of D and D realized_by P. Thus, we have focused on struc-
tural criteria where possible as the primary differentia, but have
utilized other types of differentia when necessary. This ﬂexibility
is required to adhere to the commonly accepted biological deﬁni-
tions of individual cell types.
The Cell Ontology has been developed heretofore as an OBO-for-
matted ontology, and in developing the hematopoietic terms, we
have relied on OBO-Edit 2.0 for editing the ontology, in conjunction
with a text-editor for simpler modiﬁcations of the ontology ﬁle [9].
OBO-Edit provides textual and graphical interfaces that facilitate
many aspects of ontology development, including the formation
of cross-products, and the program worked well for our purposes.3. Results
Reﬂecting the above considerations, we have taken a two-stage
approach to further development of the hematopoietic cells in the
Cell Ontology. In the ﬁrst stage, which is now complete, we revised
current terms and added new terms so that all hematopoietic cell
type terms now have textual deﬁnitions that contain all the neces-
sary details to deﬁne the cells logically. These terms have been di-
rectly incorporated into the existing ontology. Fig. 2A shows a
typical OBO term stanza for one of these new terms, ‘‘induced T-
regulatory cell.”
We have also separated the hematopoietic terms from the com-
plex hierarchy of the original CL as much as possible, so that the
section of the ontology containing these terms represents a true
is_a hierarchy. Fig. 1B shows the simpliﬁed hierarchy for the cell
type ‘‘macrophage.” In restructuring the ontology for the hemato-
poietic cells, we have eliminated the multiple inheritance via the
artifactual high-level terms such as ‘‘cell by histology.” ‘‘cell by nu-
clear number,” or ‘‘cell by function.” Instead, information about
cellular qualities is captured in the textual deﬁnitions where it is
relevant, and is being used to build logical deﬁnitions for the cell
types in the second stage of the work, as described below.
The version of the CL incorporating the changes in the hemato-
poietic terms accomplished in this ﬁrst stage of revision has been
given the working name ‘‘CL1.5”. (Note this does not refer to the
CVS revision number within the cell.obo ﬁle itself, but rather the
data-version tag.) Within CL1.5 there are many concrete improve-
ments to CL content in the area of hematopoietic cells. We have
created many new terms for individual cell types, including over
40 terms for T-lineage cells, over 40 terms for B-lineage cells, sev-
eral natural killer cell terms, over 30 terms for monocytes and mac-
rophages, and over 30 terms for dendritic cells. Other new terms
have been introduced for various hematopoietic progenitor cell
types. As discussed above, most of these new terms have been de-
ﬁned by structural criteria (protein expression) sometimes in con-
junction with functional or anatomical relationships. An exception
to this general rule is that most of the new macrophage terms are
deﬁned based on their anatomical location with protein expression
criteria added where supported by the literature. All these new and
revised terms are present in the publicly available version of the CL
(www.obofoundry.org/cgi-bin/detail.cgi?id=cell). We have pro-
vided references within the ontology to published articles or text-
books that were used in developing the individual deﬁnitions for
the majority of hematopoietic terms. For the rest, the term refer-
ences are to the curators who developed the deﬁnitions based on
their expert knowledge. All terms in the CL that were revised or
developed during the NIAID workshop and its follow-up work have
also been given the reference ID GO_REF:0000031, which refers to
78 A.D. Diehl et al. / Journal of Biomedical Informatics 44 (2011) 75–79a brief description of the workshop in a list of references main-
tained at the GO Consortium web site (www.geneontology.org).
The ontology structure has been improved in important areas
such as T cell and B cell development. Lineage relationships via
the develops_from relation are now provided for many additional
cell types. In general the hematopoietic terms are presented as spe-
cies neutral, but species-speciﬁc information is incorporated in
some deﬁnitions where necessary and comments have been added
to provide clarity to data annotators, especially in cases where cer-
tain cell types have no close homologue in another species.
The second stage of development will be the extension of the
hematopoietic term deﬁnitions into full cross-products as dis-
cussed above. The revised deﬁnitions provided in the ﬁrst step will
enable this extension in a fairly efﬁcient manner depending upon
the availability of the necessary terms in external ontologies. The
initial step in this direction was taken by Masci and colleagues,
who developed an ontology for dendritic cell types DC–CL, which
is based on cross-product principles and is the foundation of the
revised dendritic cell terms in CL1.5 [10]. DC–CL terms for types
of dendritic cells are based on structural criteria (surface protein
expression) with a few cell types also deﬁned by relationships to
functions or dispositions. DC–CL utilizes an expanded range of
relation types based on those in the OBO Relation Type Ontology
(www.obofoundry.org/cgi-bin/detail.cgi?id=relationship) in order
to be more expressive about the cellular location and degree of
protein expression (e.g. has_plasma_membrane_part,
has_high_membrane_amount). We intend to use these relations to-
gether with the deﬁnitions provided by Masci et al. to provide log-
ical deﬁnitions for the hematopoietic terms.A
id: CL:0000902
name: induced T-regulatory cell
def: "CD4-positive alpha-beta T cell with the 
phenotype CD25-positive, CTLA-4-positive, and 
FoxP3-positive with regulatory function."
is_a: CL:0000792 ! CD4-positive, CD25-positive, 
alpha-beta regulatory T cell
relationship: develops_from CL:0000896 ! 
activated CD4-positive, alpha-beta T cell
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Fig. 2. Examples of improvement in the representation of hematopoietic cells. (A) OB
regulatory cell.” (B) OBO term stanza representative of CL2.0 showing logical deﬁnitio
(synonyms in A and B omitted for brevity).Recently, the Gene Ontology Consortium obtained an ARRA
Competitive Revision grant to allow the cross-product/logical def-
inition approach to be extended to the whole of the CL to create
version ‘‘CL2.0.” As a ﬁrst step we are developing the hematopoi-
etic terms of CL1.5 into an external mini-ontology, ‘‘Hemo-CL,”
based on these cross-products. A provisional version of Hemo-CL
is available at obo.cvs.sourceforge.net/viewvc/obo/obo/ontology/
anatomy/cell_type/hemo_CL.obo. Fig. 2B shows the OBO term
stanza for term ‘‘induced T-regulatory cell” as it is represented in
Hemo-CL. This is illustrated graphically in Fig. 2C. We are working
with the curators of the Protein Ontology to ensure that the 600+
protein terms needed for Hemo-CL are found in the Protein Ontol-
ogy. Completion of the Hemo-CL subontology is expected in 2010.
4. Discussion
The Cell Ontology is an essential core component of the OBO
Foundry and has great potential for aiding in data annotation and
analysis. With the improvements implemented for CL1.5 and
planned for hemo-CL/CL2.0, we expect the CL to fulﬁll its promise
in the area of hematopoietic cell representation. The ontology now
has fairly complete coverage of these cell types in an improved
hierarchy and with up-to-date molecular deﬁnitions. These
changes will enable more robust inference across the ontology,
provide greater utility for annotation of hematopoietic cell type
data, and strengthen the use of the CL as a reference ontology.
Our two-stage approach has worked well in carrying out the
needed additions and revisions in the ontology content in this area,
and in outlining a clear plan for the full restructuring of the hema-L:0000902
e: induced T-regulatory cell
espace: cell
: "CD4-positive alpha-beta T cell with the phenotype 
25-positive, CTLA-4-positive, and FoxP3-positive 
 regulatory function."
: CL:0000792 ! CD4-positive, CD25-positive, 
a-beta regulatory T cell
rsection_of: CL:0000792 ! CD4-positive, CD25-
itive, alpha-beta regulatory T cell
rsection_of: has_part PRO:000001350 ! forkhead 
 protein P3
rsection_of: has_plasma_membrane_part 
O:000001852 ! cytotoxic T-lymphocyte protein 4
tionship: develops_from CL:0000896 ! activated 
4-positive, alpha-beta T cell
O term stanza representative of CL1.5 term deﬁnitions for the term ‘‘induced T-
n of the same term as in (A). (C) Graphical view of the term relationships in (B)
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out the full restructuring of the hematopoietic cells, and we will
work closely with other communities of biologists to improve
the CL in a variety of subﬁelds based on our approach outlined
here. We will also work with formal ontologists on the set of rela-
tions that will be used in the cross-product deﬁnitions. The rela-
tions deﬁned by Masci et al. such as has_plasma_membrane_part,
as well as the capable_of relation introduced here could be consid-
ered undesirable as they potentially open the door to a slew of
unprincipled relations. We maintain that these ‘macro’ style rela-
tions are both useful and principled, as they are formally deﬁned
in terms of existing relations and classes, and can be expanded
out to a more verbose form if necessary. However, we will continue
to work with the wider community of OBO Foundry developers to
come up with a solution that is optimal for everyone.
The improvements in the representation of hematopoietic/im-
mune cells in the Cell Ontology will have a great impact on the util-
ity of the ontology in a variety of areas. For instance, classiﬁcation
of cell types based on ﬂow cytometry data will now be possible
from the molecular deﬁnitions of particular cell types in the CL.
The hierarchical nature of the subsumption relationships will en-
able cell types to be classiﬁed according to varying levels of detail,
depending on the number and type of ﬂow cytometry parameters
studied, corresponding to the speciﬁc cell surface molecules ex-
pressed. Thus a simple combination of markers used in a ﬂow
cytometry experiment designed to study T cells, such as using anti-
bodies against the alpha–beta T cell receptor and the CD4 and CD8
coreceptors, will allow the identiﬁcation of cell types correspond-
ing to higher level terms in the T cell hierarchy of the CL. The addi-
tion of parameters, such as CD25 or intracellular staining for
particular cytokines, will distinguish among more granular cell
types in the ontology. Furthermore, the ontology itself provides a
list of subtypes of particular high-level cell types, which can guide
a researcher in the choice of additional parameters to study. Ide-
ally, such an ontology-based ﬂow cytometry system would provide
for automated analyses and classiﬁcations of cell types in both ba-
sic research and clinical settings.
We expect also that cell type terms from the CL will be applied
in annotations not only in the GO, but in combinations with other
ontologies as well. For example, CL terms might be employed in
conjunction with terms from the Infectious Disease Ontology
(www.infectiousdiseaseontology.org) as part of a machine-read-
able description of the life history of an infectious disease within
a host. The CL can be used to describe the cell types within the host
for which a virus exhibits a speciﬁc tropism, and also to describe
the cell types of the immune system that are most active in the im-
mune response to the viral infection. In this way a canonical view
of a typical infection can be described, and clinical ﬁndings could
then be checked against this ontological based model to identify
differences between individual patient immune responses, which
may help guide the choice of therapies.
Furthermore, we expect the Cell Ontology to become a source of
important metadata for high throughput gene expression data sets,
which are often tied to particular cell types. Similarly, we see clear
value in using the CL in the labeling of images and videos of cells,and for other cases where data is derived from deﬁned cell types.
Use of CL terms to specify elements of computational and mathe-
matical models of immune responses will also facilitate more rig-
orous cross-model comparisons. Linking data identiﬁed with a
particular cell type to the corresponding CL term will allow identi-
ﬁcation of GO terms that reference the CL term in their names or
deﬁnitions. The Cell Ontology term ‘‘macrophage,” for instance, is
linked to the GO term, ‘‘macrophage differentiation” and 38 other
GO terms related to biological processes in macrophages. Many
of these GO terms have genes from particular species annotated
to them. Thus, a person viewing a cell image annotated with a par-
ticular CL term will be able ﬁnd related GO terms and their associ-
ated genes.
5. Summary
The work described herein represents a signiﬁcant advance in
the representation of hematopoietic cell types in the Cell Ontology,
and will increase the utility of the ontology for data annotation,
integration, and analysis in this domain in both research and clin-
ical settings. Additionally, the workshop approach we utilized has
provided a general framework for future development of these
terms, and indeed the whole of the CL, based on the cross-prod-
uct/logical deﬁnition approach.
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